what is the biochemical function of glucagon?
|
what is the biochemical function of insulin?
|
to trigger the release of glucose into the blood from the liver via gluconeogenesis and glycogenolysis
|
to trigger the absorption of glucose from the blood into the liver, skeletal muscle and fat tissue
|
what is Type 1 diabetes?
|
what are the biochemical features of Type 1 diabetes?
|
what is Type 2 diabetes?
|
what are the biochemical features of Type 2 diabetes?
|
insulin-dependent (absolute deficiency of insulin caused by an autoimmune condition)
|
hyperglycaemia and ketoacidosis
|
non-insulin-dependent (decreased ability of tissues to respond to normal levels of insulin)
|
hyperglycaemia
|
hypertriacylglycerolaemia
|
dyslipidaemia
|
what are the treatment options for diabetes?
|
what are examples of each?
|
what are their mechanisms of action?
|
insulin and insulin analogues
|
insulin
|
triggers the absorption of glucose from the blood into the liver, skeletal muscle and fat tissue
|
oral hypoglycemic drugs
|
insulin secretagogues (sulfonylureas & meglitinides)
|
promote insulin release from the b-cells of the pancreas by: - binding to and close ATP-sensitive K+ channels on b-cells - depolarising the cells and opens Ca2+ channels - triggering fusion of insulin granules with cell membrane
|
insulin sensitisers (biguanides & thiazolidinediones)
|
improve the response of target cells to insulin by either: - decreasing hepatic gluconeogenesis & reducing intestinal absorption of sugars (biguanides) or: - activation of peroxisome proliferator-activated receptors (thiazolidinediones)
|
a-glucosidase inhibitors
|
acarbose, miglitol, voglibose
|
competitively inhibit the action of the enzyme a-glucosidase, that breaks carbohydrates into monosaccharides
|
gastrointestinal hormones
|
glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), peptide YY (PYY)
|
-
|